Mogamulizumab treatment of refractory peripheral T-cell lymphoma following autologous stem cell transplantation: A case report

Molecular and Clinical Oncology
Yukie FujitaShosaku Nomura

Abstract

Peripheral T-cell lymphoma (PTCL) represents a small heterogeneous group of non-Hodgkin lymphoma (NHL) that accounts for ~10% of NHLs in western countries and ~25% of NHLs in Japan. The disease remains extremely difficult to treat. Therefore, novel treatment modalities are required. Mogamulizumab is a humanized immunoglobulin G1 monoclonal antibody that targets CC chemokine receptor 4. To the best of our knowledge, the efficacy of mogamulizumab in patients who are refractory to conventional chemotherapy following autologous stem cell transplantation has not been investigated previously. The present study reports a patient with PTCL who relapsed following autologous stem cell transplantation and became resistant to salvage chemotherapy, in whom mogamulizumab showed evident efficacy without severe adverse event.

References

Aug 26, 2004·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Takashi IshidaRyuzo Ueda
Feb 7, 2008·Pathology International·Ryosuke AokiKoichi Ohshima
Jan 2, 2009·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Masao NakagawaMasao Seto
Feb 18, 2010·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Toshihiko IshiiRyuzo Ueda
Feb 24, 2010·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Kazuhito YamamotoRyuzo Ueda
Nov 4, 2010·Cancer Science·Takashi Ishida, Ryuzo Ueda
Mar 13, 2014·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Michinori OguraRyuzo Ueda

❮ Previous
Next ❯

Citations

May 31, 2019·Clinical Reviews in Allergy & Immunology·Anne BordronYves Renaudineau

❮ Previous
Next ❯

Methods Mentioned

BETA
biopsy

Related Concepts

Related Feeds

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.

B-Cell Lymphoma

B-cell lymphomas include lymphomas that affect B cells. This subtype of cancer accounts for over 80% of non-Hodgkin lymphomas in the US. Here is the latest research.